EcoDrugPlus

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSCHYG00000002397
Gene Symbol: NR3C2
1 Cross references
214 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSCHYG00000005036
Gene Symbol: NOD2
1 Cross references
167 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSCHYG00000005893
Gene Symbol: OPRD1
1 Cross references
254 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSCHYG00000022698
Gene Symbol: OPRK1
1 Cross references
264 Possible Orthologues:

Opioid Receptor Mu 1

Ensembl ID : ENSCHYG00000026823
Gene Symbol: OPRM1
1 Cross references
215 Possible Orthologues:

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSCHYG00000017976
Gene Symbol: OPRL1
1 Cross references
202 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSCHYG00000026918
Gene Symbol: OXTR
1 Cross references
265 Possible Orthologues:

P21 (Rac1) Activated Kinase 4

Ensembl ID : ENSCHYG00000027097
Gene Symbol: PAK4
1 Cross references
160 Possible Orthologues:

Pancreatic Lipase

Ensembl ID : ENSCHYG00000018135
Gene Symbol: PNLIP
1 Cross references
301 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSCHYG00000023797
Gene Symbol: PTH1R
1 Cross references
199 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Alpha

Ensembl ID : ENSCHYG00000018440
Gene Symbol: PPARA
1 Cross references
455 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSCHYG00000010282
Gene Symbol: PPARD
1 Cross references
420 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).